Synapse - Howard Scher

Results (1133)

Abiraterone in metastatic prostate cancer without previous chemotherapy

Journal Article

Ryan, C. J.; Smith, M. R.; de Bono, J. S.; Molina, A.; Logothetis, C. J.; De Souza, P.; Fizazi, K.; Mainwaring, P.; Piulats, J. M.; Ng, S.; more...
New England Journal of Medicine (2013)

Fulltext@MSK | Save

The analytic validation of prostate-specific mRNA detection in whole blood by RT-PCR as a prognostic biomarker for patients with castration- resistant prostate cancer (CRPC)

Meeting Abstract

Danila, D. C.; Anand, A.; Heller, G.; Wan, M.; Zehnder, M.; Khanin, R.; Schultz, N.; Fleisher, M.; Lilja, H.; Scher, H. I.
Journal of Clinical Oncology (2012)

Fulltext@MSK | Save

Targeting castration resistant prostate cancer (CRPC) with autologous PSMA-directed CAR plus T cells

Meeting Abstract

Slovin, S. F.; Wang, X.; Borquez-Ojeda, O.; Stefanski, J.; Olszewska, M.; Taylor, C.; Bartido, S.; Scher, H. I.; Sadelain, M.; Riviere, I.
Journal of Clinical Oncology (2012)

Fulltext@MSK | Save

Cabozantinib (XL184) in chemotherapy-pretreated metastatic castration resistant prostate cancer (mCRPC): Results from a phase II nonrandomized expansion cohort (NRE)

Meeting Abstract

Smith, M. R.; Sweeney, C.; Rathkopf, D. E.; Scher, H. I.; Logothetis, C.; George, D. J.; Higano, C. S.; Yu, E. Y.; Harzstark, A. L.; Small, E. J.; more...
Journal of Clinical Oncology (2012)

Fulltext@MSK | Save

A phase II study of the androgen signaling inhibitor ARN-509 in patients with castration-resistant prostate cancer (CRPC)

Meeting Abstract

Rathkopf, D. E.; Shore, N.; Antonarakis, E. S.; Berry, W. R.; Alumkal, J. J.; Tutrone, R.; Saleh, M. N.; Redfern, C. H.; Hauke, R. J.; Liu, G.; more...
Journal of Clinical Oncology (2012)

Fulltext@MSK | Save

A phase I study of the androgen signaling inhibitor ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC)

Meeting Abstract

Rathkopf, D. E.; Morris, M. J.; Danila, D. C.; Slovin, S. F.; Steinbrecher, J. E.; Arauz, G.; Curley, T.; Rix, P. J.; Maneval, E. C.; Chen, I.; more...
Journal of Clinical Oncology (2012)

Fulltext@MSK | Save

A validated whole-blood RNA transcript-based prognostic model that predicts survival in men with castration-resistant prostate cancer

Meeting Abstract

Oh, W. K.; Kantoff, P.; Scher, H. I.; Magidson, J.; Wassmann, K.; Lee, G. S. M.; Katz, L. M.; Subudhi, S. K.; Anand, A.; Fleisher, M.; more...
Journal of Clinical Oncology (2012)

Fulltext@MSK | Save

Exploratory analysis of survival benefit and prior docetaxel (D) treatment in COU-AA-301, a phase III study of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC)

Meeting Abstract

Goodman, O. B.; Chi, K. N.; Molina, A.; Logothetis, C.; Jones, R. J.; Staffurth, J.; North, S. A.; Vogelzang, N. J.; Saad, F.; Mainwaring, P. N.; more...
Journal of Clinical Oncology (2012)

Fulltext@MSK | Save

CA184-043: A randomized, double-blind, phase III trial comparing ipilimumab versus placebo following a single dose of radiotherapy (RT) in patients (pts) with castration-resistant prostate cancer (CRPC) who have received prior treatment with docetaxel (D)

Meeting Abstract

Drake, C. G.; Scher, H. I.; Bossi, A.; van den Eertwegh, A. J. M.; McHenry, B.; Fitzmaurice, T. F.; Cuillerot, J. M.; Chin, K. M.; Gagnier, P.; Fizazi, K.; more...
Journal of Clinical Oncology (2012)

Fulltext@MSK | Save

Primary, secondary, and quality-of-life endpoint results from the phase III AFFIRM study of MDV3100, an androgen receptor signaling inhibitor

Meeting Abstract

De Bono, J. S.; Fizazi, K.; Saad, F.; Taplin, M. E.; Sternberg, C. N.; Miller, K.; Mulders, P.; Chi, K. N.; Armstrong, A. J.; Hirmand, M.; more...
Journal of Clinical Oncology (2012)

Fulltext@MSK | Save